Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.56 |
| ▸ | CA1 | P00915 | 13/20 | 0.52 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302264 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL584864 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL584177 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL585171 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3838335 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7660482 | 1.00 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL73684 | 0.97 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6898759 | 0.94 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL13684270 | 0.91 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL11788241 | 0.91 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115595134-A | Medicament composition for purifying and discharging liquid and preparation method and application thereof | 中国石油化工股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-10876034-B1 | Modified silicon dioxide material of fluorocarbon active agent type super-amphiphobic cutting-carrying agent suitable for water-based drilling fluid and preparation method thereof | CHINA UNIVERSITY OF PETROLEUM (BEIJING) (CN) | 2020-12-29 | — | — | US | disclosed |
| CN-109337657-B | Modified silicon dioxide material suitable for fluorocarbon active agent type super-amphiphobic chip carrying agent for water-based drilling fluid and preparation method and application thereof | 中国石油大学(北京) | 2020-04-24 | — | — | CN | disclosed |
| US-8304580-B2 | Method for producing tris(perfluoroalkanesulfonyl)methide acid salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2080753-B1 | METHOD FOR PRODUCING TRIS(PERFLUOROALKANESULFONYL)METHIDE ACID SALT | CENTRAL GLASS CO LTD (JP) | 2012-02-15 | — | — | EP | disclosed |
| US-20100022803-A1 | Method for Producing Tris(Perfluoroalkanesulfonyl)Methide Acid Salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2080753-A1 | METHOD FOR PRODUCING TRIS(PERFLUOROALKANESULFONYL)METHIDE ACID SALT | Central Glass Company, Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | CA2 4820/4885CA1 4528/4885MMP1 3988/4885 |
| US-20100022803-A1 | Method for Producing Tris(Perfluoroalkanesulfonyl)Methide Acid Salt | PFAS, AFF1, AFF2 | CA2 168/4885CA1 426/4885MMP1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.